NF2-SWN Accelerator Impact Report
A comprehensive report of the first year of CTF's NF2-SWN Accelerator Initiative, which is focused on improving drug selection through the development of innovative testing models and the development of gene therapy options that address the underlying genetic causes of NF2-related schwannomatosis.
A comprehensive report of the first year of CTF's NF2-SWN...
A comprehensive report of the first year of CTF's NF2-SWN Accelerator Initiative, which is focused on improving drug selection through the development of innovative testing models and the development of...
Patient Engagement
A trifold brochure about CTF's Patient Engagement program, which trains patients to take an active part in neurofibromatosis and schwannomatosis research.
A trifold brochure about CTF's Patient Engagement program, which trains...
A trifold brochure about CTF's Patient Engagement program, which trains patients to take an active part in neurofibromatosis and schwannomatosis research.
What is a Clinical Trial
A printable resource for those in the NF community seeking information about clinical trials and the factors to be considered before participating in a clinical trial.
A printable resource for those in the NF community seeking...
A printable resource for those in the NF community seeking information about clinical trials and the factors to be considered before participating in a clinical trial.
What is a Clinical Trial (Spanish)
A Spanish translation of our printable resource for those in the NF community seeking information about clinical trials and the factors to be considered before participating in a clinical trial.
A Spanish translation of our printable resource for those in...
A Spanish translation of our printable resource for those in the NF community seeking information about clinical trials and the factors to be considered before participating in a clinical trial.
MEK Makes A Difference
Stories of the clinical trial successes that led to the FDA approval of the MEK inhibitor selumetinib (Koselugo).
Stories of the clinical trial successes that led to the...
Stories of the clinical trial successes that led to the FDA approval of the MEK inhibitor selumetinib (Koselugo).
Top Ten NF Advancements in 2023
A summary of the Children's Tumor Foundation's Top Ten Advancements in NF Research in 2023.
A summary of the Children's Tumor Foundation's Top Ten Advancements...
A summary of the Children's Tumor Foundation's Top Ten Advancements in NF Research in 2023.
